Le Lézard
Classified in: Health
Subjects: NPT, LEG, AVO

PCMA Applauds Administration's Effort to Reduce Opioid Abuse


WASHINGTON, Feb. 2, 2018 /PRNewswire-USNewswire/ -- The Pharmaceutical Care Management Association (PCMA) released the following statement on the Centers for Medicare and Medicaid's (CMS) 2019 Medicare Advantage and Part D Advance Notice Part II and Draft Call Letter:

"By proposing to allow plans to implement a seven-day limit on certain opioids, CMS is taking an important step in the fight against opioid abuse. The next even more impactful step is for Congress to pass legislation (H.R. 3528, the 'Every Prescription Conveyed Securely Act') requiring e-prescribing of controlled substances in Medicare.

PCMA looks forward to working with Secretary of Health & Human Services Alex Azar and Food and Drug Administration Commissioner Dr. Scott Gottlieb on these and other policy solutions to address the opioid crisis."

Last year, PCMA submitted a set of policy solutions on the opioid crisis to Commissioner Gottlieb, including:  

PCMA is the national association representing America's pharmacy benefit managers (PBMs). PBMs administer prescription drug plans for more than 266 million Americans who have health insurance from a variety of sponsors including: commercial health plans, self-insured employer plans, union plans, Medicare Part D plans, the Federal Employees Health Benefits Program (FEHBP), state government employee plans, Medicaid plans, and others.

SOURCE Pharmaceutical Care Management Association


These press releases may also interest you

at 06:45
On April 17, FAIR Health hosted a webinar entitled "Fifteen Years of Advancing Health Literacy and Cost Transparency: A Free Webinar on FAIR Health's Award-Winning Consumer Resources." This webinar offered a comprehensive review of FAIR Health's...

at 06:41
Provident Healthcare Partners ("Provident"), a leading healthcare investment banking firm, announced it has advised Community Eye Care Specialists ("CECS") in its affiliation with EyeSouth Partners ("EyeSouth"). CECS is a leading comprehensive...

at 06:38
"According to the latest research study, the demand for Biologic Therapeutic Drugs: Technologies and Global Markets expected to grow from $452.9 in 2023 to reach $823.4 billion by the end of 2028 at a compound annual growth rate (CAGR) of 12.7%...

at 06:35
Morphoceuticals Inc., a new biotechnology company pioneering AI-guided electroceuticals for tissue repair and organ regeneration, today announced the appointment of veteran biotech executive Jim Jenson, PhD, as CEO. Jenson joins a growing team and...

at 06:35
"According to the latest research study, the...

at 06:31
Targeted nutrient support for Hormonal Balance, Egg Quality, Cycle Regularity and More...



News published on and distributed by: